Generic Semaglutide on the Horizon

The key ingredient, semaglutide, is protected by numerous patents, but the first of these are set to expire in 2026 in major markets like China, Brazil, India, and Canada. In the United States, however, key patents for semaglutide are not expected to expire until December 2031. Without insurance, brand-name drugs containing semaglutide are costly, with Ozempic's list price around $1,027 per month and Wegovy at approximately $1,349 per month in the U.S. Prices in other high-income countries are often significantly lower due to government negotiations. The introduction of generics is expected to dramatically lower costs, with some analysts predicting price reductions of 60-70%. In India, where the patent expires in March 2026, generic versions could be priced nearly 50% lower than the current branded options. Danish pharmaceutical company Novo Nordisk is the original developer of semaglutide and has been actively defending its patents in court. The company holds dozens of patents related to the drug's formulation, delivery methods, and dosing strategies. A number of other pharmaceutical companies are also preparing to enter the market. Companies like Sun Pharma, Dr. Reddy's Laboratories, and Zydus Lifesciences are among those expected to launch their own versions of semaglutide. Before they can be sold, any generic version must go through a rigorous approval process with regulatory bodies like the FDA. Manufacturers must prove their product is "bioequivalent" to the original, meaning it delivers the same amount of the active ingredient to the body in the same timeframe.